AzTrials
AzTrials

MouthwashesPhase 3NCT07351370

Effects of Two Daily CHX Mouthrinses on Plaque, Gingivitis and Staining

A Phase 3 study testing chlorhexidine/ cetylpyridinium chloride/ hydrogen peroxide mouthwash and Chlorhexidine/ cetylpyridinium chloride in people with Mouthwashes and Chlorhexidine, run by Dental School at 1 site in Greece.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Τhe aim of this randomized clinical trial was to investigate the efficacy of two daily mouth rinses containing CHX and different combinations of H2O2 and CPC, when used adjunctive to mechanical oral hygiene, and compare them with a placebo mouth rinse. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Mouthwashes, Chlorhexidine, Dental Plaque
What is being tested?
chlorhexidine/ cetylpyridinium chloride/ hydrogen peroxide mouthwash and Chlorhexidine/ cetylpyridinium chloride
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
81 participants
Where
1 siteGreece
Study dates
15 Jan 2022to 20 Jul 2022
Phase
Phase 3
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Adult patients (≥18 years old)
  • Presence of at least 24 teeth
  • Presence of teeth #23-13 and #43-33
  • Gingival Index (GI) ≤30% (Lindhe, 1981)
  • No interdental clinical attachment loss (CAL) at ≥2 non-adjacent teeth or buccal/oral CAL ≥3 mm with probing pocket depth (PPD) >3 mm at ≥2 teeth (Tonetti et al., 2019)
  • No known allergy to chlorhexidine (CHX), hydrogen peroxide (H₂O₂), or cetylpyridinium chloride (CPC)
Show all 11Show fewer
  • No fixed or removable orthodontic appliances or removable prostheses
  • No use of systemic antibiotics within the 3 months prior to the study
  • Non-smokers or light smokers (<5 cigarettes/day)
  • Non-pregnant and non-lactating women
  • Absence of crowns, fixed partial dentures, or class III/IV/V composite restorations covering more than one-third of the crown, and no deep dental caries extending into dentine

Who cannot join

  • Presented with signs of hypersensitivity, severe irritation, or discomfort during the experimental period
  • Were not compliant with the experimental protocol

Trial locations and contacts

1 site in 1 country.

Greece1 site
  • NKUA School of Dentistry

    Athens, Attica

Other trials in Greece

About this study

Official title: Efficacy of Two Daily - Use CHX Based Mouth Rinses on Microbial Biofilm Accumulation, Gingivitis Development, and Staining: a Randomized Clinical Trial

Τhe aim of this randomized clinical trial was to investigate the efficacy of two daily mouth rinses containing CHX and different combinations of H2O2 and CPC, when used adjunctive to mechanical oral hygiene, and compare them with a placebo mouth rinse. The primary outcomes evaluated were changes in i) bacterial biofilm accumulation, ii) gingival inflammation, and iii) tooth staining. Secondarily, patient's satisfaction and perspective after the use of these formulations was assessed.

Read the detailed description

Trial design: This is a single-center, randomized, controlled, double-blind, parallel-design, 3- month clinical trial that compares the effectiveness of two different mouth rinses: 1) CHX 0.05% + CPC 0.05% + H2O2 0.8%, and 2) CHX 0.05% + CPC 0.05% with a placebο mouth rinse containing the same color as CHX mouth rinses but without antimicrobial agents.

Experimental phases: Following patient screening and selection, individuals received written details about the products and the research objectives, and those who volunteered for the study signed a consent form. All participants underwent scaling, air polishing, and received oral hygiene instructions. Patients were instructed to abstained from using any oral rinses for the following two weeks until they entered the trial. The aim of this preparatory phase was to allow only participants with low PI and GI scores (<15%) to take part in the clinical trial. Individuals with PI and GI ≥ 15% were re-enrolled in the two-weeks preparation phase and were reevaluated for suitability to participate in the trial.

After the preparatory phase, baseline (V0) measurements of PI, GI and stain index (SI) were recorded, and subjects were randomly allocated in one of the three following groups based on the different mouth rinse they received to use:

Group 1: CHX 0.05%+ CPC 0.05% + H2O2 0.8%. Group 2: CHX 0.05% + CPC 0.05% Group 3: Placebo

As a double-blind clinical study, neither the periodontist nor the participants are aware of the actual assigned treatment. In case of immediate unblinding of the patient (e.g., serious adverse events), the researcher has obtained opaque identical envelopes containing information regarding the treatment group to which the participant belongs. In the event of unblinding, the date/time and reason for unblinding are recorded in the research database.

All participants were instructed to rinse for 3 months for 1 minute twice a day with 15 ml of the provided solution. They were also instructed to refrain from eating or drinking for at least half an hour after rinsing, and to avoid intake of more than two glasses of coffee, tea or red wine daily.

The oral rinses were placed in opaque plastic containers of the same color, and with a capacity of 1500 ml. The containers were pre-labeled with the individual patient's serial number, so that both the patients and the examiner were unaware of which of the three oral rinses was being used each time.

At the 1-month (V1), 2-months (V2) and 3-months (V3) re-evaluation, PI, GI, and SI, were recorded as described below. In addition, the examiner monitored for potential side effects, and weighed the containers to evaluate patient's compliance. At the end of the trial a questionnaire was given to the participants to assess the patient's perspective on possible secondary effects, such as taste alteration, staining, burning feeling, and irritation.

Clinical measurements

All measurements were performed by the same examiner (periodontist), who was unaware of the group allocation. The following clinical parameters were evaluated:

  • PI (Turesky et al. (1970) modification of the Quigley and Hein index (1962))
  • Percentages of dental surface covered by dental plaque (PA%) (Pretty et al., 2005, Sagel et al., 2000).
  • GI (Löe and Silness (1963))
  • SI (Lobene (1968))
  • Time of professional mechanical removal at V3

Questionnaire Patients' perception of the product and possible adverse effects were registered in the questionnaire patients had to fill in, in the last visit, by placing a mark in a 10 cm visual analog scale (VAS). (García-Gargallo et al.2017)

Being tested
chlorhexidine/ cetylpyridinium chloride/ hydrogen peroxide mouthwash, Chlorhexidine/ cetylpyridinium chloride, Placebo
Medical subject headings
Dental Plaque, Periodontal Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • chlorhexidine/ cetylpyridinium chloride/ hydrogen peroxide mouthwashDrug

    All participants were instructed to rinse for 3 months for 1 minute twice a day with 15 ml of the provided solution.

  • Chlorhexidine/ cetylpyridinium chlorideDrug

    All participants were instructed to rinse for 3 months for 1 minute twice a day with 15 ml of the provided solution

  • PlaceboOther

    All participants were instructed to rinse for 3 months for 1 minute twice a day with 15 ml of the provided solution

Study groups in NCT07351370
Study groupRoleWhat they receive
chlorhexidine 0.05% + cetylpyridinium chloride 0.05% and hydrogen peroxide 0.8%ExperimentalParticipants rinsed twice daily for 3 months with a mouthwash containing chlorhexidine 0.05% + cetylpyridinium chloride 0.05% and hydrogen peroxide 0.8% , as adjunct to conventional mechanical oral hygiene. All participants received supragingival prophylaxis and oral hygiene reinforcement prior to the intervention.
Receives: Drug: chlorhexidine/ cetylpyridinium chloride/ hydrogen peroxide mouthwash
CHX 0.05% + CPC 0.05%ExperimentalParticipants rinsed twice daily for 3 months with a mouthwash containing chlorhexidine 0.05% and cetylpyridinium chloride 0.05% , as adjunct to conventional mechanical oral hygiene. All participants received supragingival prophylaxis and oral hygiene reinforcement prior to the intervention.
Receives: Drug: Chlorhexidine/ cetylpyridinium chloride
placebo mouthwashPlacebo comparatorParticipants rinsed twice daily for 3 months with placebo mouthwash, as adjunct to conventional mechanical oral hygiene. All participants received supragingival prophylaxis and oral hygiene reinforcement prior to the intervention.
Receives: Other: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. change in plaque index (PI)

    change in dental plaque accumulation assessed using the plaque index (PI)

    Measured: baseline, 1 month, 2 months and 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Jan 2026
  2. Study start15 Jan 2022
  3. Primary completion20 Jul 2022
  4. Study completion20 Jul 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
The interventional study model is a single-center, randomized, controlled, double-blind, parallel-design clinical trial spanning over 3 months. It compares the efficacy of two mouth rinses: 1) CHX 0.05% + CPC 0.05% + H2O2 0.8%, and 2) CHX 0.05% + CPC 0.05%, with a placebo. Participants undergo screening, sign consent forms, and receive oral hygiene instructions before being randomly allocated to one of the three groups. They rinse twice daily for 3 months, and oral health parameters are assessed at baseline and monthly intervals. Compliance is monitored, and potential side effects are evaluated. Participants provide feedback via a questionnaire at the trial's end.
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
81 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07351370
Sponsor's protocol ID
DentalSchool
Status last verified
Apr 2026
First submitted
4 Jan 2026
Last updated
8 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing chlorhexidine/ cetylpyridinium chloride/ hydrogen peroxide mouthwash and Chlorhexidine/ cetylpyridinium chloride in people with Mouthwashes and Chlorhexidine, run by Dental School at 1 site in Greece.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 11 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Greece. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

change in plaque index (PI) (time frame: baseline, 1 month, 2 months and 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in